(Q45258992)

11 December 2017

title

Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma (English)

1 reference

11 December 2017

1 reference

1 reference

John M Weiler

1

1 reference

11 December 2017

Robert A Nathan

2

1 reference

11 December 2017

Ned T Rupp

3

1 reference

11 December 2017

Christopher J Kalberg

4

1 reference

11 December 2017

Amanda Emmett

5

1 reference

11 December 2017

Paul M Dorinsky

6

1 reference

11 December 2017

publication date

1 January 2005

1 reference

Annals of Allergy, Asthma & Immunology

11 December 2017

published in

1 reference

11 December 2017

volume

94

1 reference

11 December 2017

issue

1

1 reference

11 December 2017

page(s)

65-72

1 reference

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Effect of long-term salmeterol treatment on exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

Long-term effects of budesonide or nedocromil in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961288-4

7 January 2021

10.1016/S1081-1206(10)61288-4

Identifiers

DOI

1 reference

11 December 2017

1 reference